Clinical Trial Update: Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) [Phase 2]

View source ↗

Summary

Phase 2 study P02143 evaluating temozolomide for brain metastases from non-small-cell lung cancer has been terminated. The sponsor is Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Brain Neoplasms
• Non-small Cell Lung Cancer

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED